Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUTTONS-001: Umbrella Study in ES-SCLC
NCT07172412Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of DLL3-CAR-NK cells, selinexor and anlotinib in small cell lung cancer (SCLC) (3 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Progression-Free Survival at 1 year, Objective Response Rate at 1 year and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
DLL3-CAR-NK cellsselinexoranlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07172412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172412.